ANTIMICROBIAL VIEWPOINTS – Information for authors

In the antimicrobial viewpoints series, we invite individuals with international expertise in an area of antimicrobial resistance (AMR) to share their knowledge and opinions about the status and the future challenges of this field.

We invited you to write an antimicrobial viewpoint article – what's next?

We will develop the topic of your article with you. We usually try to make suggestions to our guest authors, but we value your feedback and are happy to discuss your topic of choice. We need to make sure that the topic is in line with the scope of our Viewpoint articles. Therefore, please do not start drafting the article before the topic is agreed.

Once we have agreed on a topic, we will agree on a deadline for the submission. We are grateful for your support and understand that you have many other commitments. Therefore, we are flexible and can find a date that is achievable for you. However, we ask that you alert us as soon as possible if you struggle to write your contribution on time.

Once submitted, your draft will be reviewed by experts (for further information about the questions we ask them, please see here) and edited to ensure that it is suitable for our audience. We may ask you to add a little more detail or shorten the text. Please rest assured that we will only publish the text once you have approved it. Prior to publication, you will need to complete a conflict of interest form, this can be found here

To give readers some information about our authors, we will publish your picture and a brief biography together with the article.

Please keep the following points in mind for your article:

- The article should have a maximum length of **800 words**.
- The article should **not** be **promotional** for a company or product but of course companies and products can be mentioned within the bigger picture.
- Our target audience includes everyone with an interest in antimicrobial R&D and the wider field of AMR, including early career researchers as well as seasoned experts; lab scientists and physicians as well as those who may or may not have a deep understanding of drug development, clinical trials, regulatory affairs, and microbiology. Please keep this in mind when developing your article and provide sufficient, but brief, background information.
- These articles should not be factual literature reviews or "About" sections from organizations' websites that may have been written by another person. Instead, the article should reflect your own expert opinions and experience in the field. Wherever possible, opinions must be supported with evidence from scientific articles (these should be referenced) and opposing arguments should be considered. This perspective will give the article extra value. For example, you can complement the facts by mentioning your own professional journey related to these, e.g.:
    - … in my role as ___, I have seen ___
    - … when working on the development of this drug/report/etc., I learned that ___
    - … I think it is essential that ___
    - … in my ___ year career in the field of antimicrobials, I have come across ___
- **Prior to publication all articles must be approved by the GARDP management team who act as the Editorial Board for the Viewpoint articles.**
- All articles have a disclaimer which distances GARDP from the content of the text. This does not necessarily mean that we disagree with your views. However, we want to give authors the freedom to express their opinions, even if they are not **fully** aligned with GARDP's. Therefore, we need to take this measure to indicate that there may be a difference between GARDP's views and those of our guest authors.

- The topic or title of the articles may be provocative, but we request that your article remains respectful of the different backgrounds, culture and expertise of our readers and is supported by rational arguments.
- All articles are published using the Vancouver style of referencing.
- Please refer to our Acceptable Use Policy as well as our Terms of Use for more information.